X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy's net up 146% - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Nov 1, 2000

    Dr. Reddy's net up 146%

    In line with the impressive results from other Indian pharmaceutical companies, Dr. Reddy's has also reported impressive results. While the turnover has jumped 45% in the second quarter vis–a–vis the corresponding period last year, the net profit has galloped 146%.

    (Rs m) 2QFY00 2QFY01 Change
    Sales 1,136 1,646 44.9%
    Other Income 10 23 128.2%
    Expenditure 936 1,214 29.7%
    Operating Profit (EBDIT) 200 432  
    Operating Profit Margin (%) 17.6% 26.3%  
    Interest 29 44 53.1%
    Depreciation 41 66 59.7%
    Profit before Tax 140 345 146.8%
    Other Adjustments      
    Tax 20 50 150.0%
    Profit after Tax/(Loss) 120 295 146.2%
    Net profit margin (%) 10.5% 17.9%  
    Earnings per share* 18.07 44.49  
    (annualised)      

    One of the key reasons for the impressive growth in profitability is the surge in sales of finished dosages both in the domestic and the international markets. While exports to Russia have almost tripled (partly due to the fact that the company had tightened supplies to the Russian market last year), exports to other international markets have grown by 95% quarter on quarter. Domestic finished dosages have grown by 35% outstripping the 12% industry growth by a mile.

    The company's major brands Omez (anti–ulcer) and Nise (anti–pain) continue to ranked among the top 25 brands as per ORG. Besides, the company has introduced two new brands Irnocam and Cytogem for colorectal and lung cancer respectively in the current quarter.

    Interest cost and depreciation for the quarter have increased over 50% primarily due to additional borrowings and capex respectively on account of the acquisition of American Remedies. The company has however not clarified the extent of contribution of American Remedies to the current quarter's turnover.

    The stock quotes at Rs 1,380 which implies an earnings multiple of 31 times second quarter annualised earnings. The net profit is however, in line with our full year projections of a net profit of Rs 1,130 m. Our projections however take into account the merger with group company Cheminor Laboratories. Dr. Reddy's is expected to merge the same in the current year only. We would rather wait for the third quarter results before revising our projections.

     

     

    Equitymaster requests your view! Post a comment on "Dr. Reddy's net up 146%". Click here!

      
     

    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    DR. REDDYS LAB SHARE PRICE


    Aug 18, 2017 11:03 AM

    TRACK DR. REDDYS LAB

    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    DR. REDDYS LAB - TORRENT PHARMA COMPARISON

    Compare Company With Charts

    COMPARE DR. REDDYS LAB WITH

    MARKET STATS